uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
Show others and affiliations
2006 (English)In: Journal of the American Society of Nephrology, ISSN 1046-6673, Vol. 17, no 2, 581-589 p.Article in journal (Refereed) Published
Abstract [en]

Sirolimus (SRL) is a mammalian target of rapamycin inhibitor that, in contrast to cyclosporine (CsA), has been shown to inhibit rather than promote cancers in experimental models. At 3 mo +/- 2 wk after renal transplantation, 430 of 525 enrolled patients were randomly assigned to remain on SRL-CsA-steroids (ST) or to have CsA withdrawn and SRL troughs increased two-fold (SRL-ST). Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis. Mean annualized rates of skin malignancy were calculated, and the relative risk was determined using a Poisson model. Malignancy-free survival rates for nonskin malignancies were compared using Kaplan-Meier estimates and the log-rank test. At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis). The relative risks for both basal and squamous cell carcinomas were significantly reduced. Kaplan-Meier estimates of nonskin cancer were 9.6 versus 4.0% (SRL-CsA-ST versus SRL-ST; P = 0.032, intention-to-treat analysis). Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma. Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA. Longer follow-up and additional trials are needed to confirm these promising results.

Place, publisher, year, edition, pages
2006. Vol. 17, no 2, 581-589 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-10957DOI: 10.1681/ASN.2005090993ISI: 000242120200034PubMedID: 16434506OAI: oai:DiVA.org:uu-10957DiVA: diva2:38725
Available from: 2007-05-07 Created: 2007-05-07 Last updated: 2011-05-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Claesson, Kerstin
By organisation
Transplantation Surgery
In the same journal
Journal of the American Society of Nephrology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 160 hits
ReferencesLink to record
Permanent link

Direct link